HIV evades RNA interference directed at TAR by an indirect compensatory mechanism.

HIV can rapidly evolve when placed under selective pressure, including immune surveillance or the administration of antiretroviral drugs. Typically, a variant protein allows HIV to directly evade the selective pressure. Similarly, HIV has escaped suppression by RNA interference (RNAi) directed against viral RNAs by acquiring mutations at the target region that circumvent RNAi-mediated inhibition while conserving necessary viral functions. However, when we directed RNAi against the viral TAR hairpin, which plays an indispensable role in viral transcription, resistant strains were recovered, but none carried a mutation at the target site. Instead, we isolated several strains carrying promoter mutations that indirectly compensated for the RNAi by upregulating viral transcription. Combining RNAi with the application of an antiviral drug blocked replication of such mutants. Evolutionary tuning of viral transcriptional regulation may serve as a general evasion mechanism that may be targeted to improve the efficacy of antiviral therapy.

[1]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[2]  Christopher D. Richardson,et al.  Hepatitis C Virus Replicons Escape RNA Interference Induced by a Short Interfering RNA Directed against the NS5b Coding Region , 2005, Journal of Virology.

[3]  G. Hutvagner,et al.  A microRNA in a Multiple-Turnover RNAi Enzyme Complex , 2002, Science.

[4]  M. Sioud,et al.  Gene silencing in mammalian cells by preformed small RNA duplexes. , 2002, Biochemical and biophysical research communications.

[5]  B. Berkhout,et al.  Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type 1 Vaccine Strains , 1999, Journal of Virology.

[6]  D. Baltimore,et al.  Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Ben Berkhout,et al.  Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition , 2004, Journal of Virology.

[8]  P. Luciw,et al.  Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat. , 1989, Genes & development.

[9]  D. Baltimore,et al.  The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Carr Toxicity of antiretroviral therapy and implications for drug development , 2003, Nature Reviews Drug Discovery.

[11]  J. Rossi,et al.  Rapid assessment of anti-HIV siRNA efficacy using PCR-derived Pol III shRNA cassettes. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  G. Nabel,et al.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells , 1990, Nature.

[13]  Evaluating the binding affinities of NF-kappaB p50 homodimer to the wild-type and single-nucleotide mutant Ig-kappaB sites by the unimolecular dsDNA microarray. , 2003, Analytical biochemistry.

[14]  J S Wall,et al.  DNA looping and Sp1 multimer links: a mechanism for transcriptional synergism and enhancement. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Berro,et al.  HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR , 2007, BMC Molecular Biology.

[16]  J. Stone,et al.  Poliovirus Escape from RNA Interference: Short Interfering RNA-Target Recognition and Implications for Therapeutic Approaches , 2005, Journal of Virology.

[17]  D. Chen,et al.  Transcription elongation factor P‐TEFb mediates Tat activation of HIV‐1 transcription at multiple stages , 1998, The EMBO journal.

[18]  Joshua N. Leonard,et al.  Computational Design of Antiviral RNA Interference Strategies That Resist Human Immunodeficiency Virus Escape , 2005, Journal of Virology.

[19]  K. Crandall,et al.  The causes and consequences of HIV evolution , 2004, Nature Reviews Genetics.

[20]  T. Okamoto,et al.  Transcriptional Repression of Human Immunodeficiency Virus Type 1 by AP-4* , 2006, Journal of Biological Chemistry.

[21]  Stacy L DeRuiter,et al.  RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. Wintersberger,et al.  Histone Deacetylase 1 Can Repress Transcription by Binding to Sp1 , 1999, Molecular and Cellular Biology.

[23]  Stefan L Ameres,et al.  Molecular Basis for Target RNA Recognition and Cleavage by Human RISC , 2007, Cell.

[24]  Michael T. McManus,et al.  Gene silencing in mammals by small interfering RNAs , 2002, Nature Reviews Genetics.

[25]  Ben Berkhout,et al.  HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome , 2005, Nucleic acids research.

[26]  M. Horikoshi,et al.  Repression of HIV-1 transcription by a cellular protein. , 1991, Science.

[27]  R. Cheynier,et al.  Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro , 1991, Journal of virology.

[28]  A. Kimura,et al.  Regulation of interaction of the acetyltransferase region of p300 and the DNA‐binding domain of Sp1 on and through DNA binding , 2000, Genes to cells : devoted to molecular & cellular mechanisms.

[29]  Anastasia Khvorova,et al.  Induction of the interferon response by siRNA is cell type- and duplex length-dependent. , 2006, RNA.

[30]  J. S. Sullivan,et al.  Genomic Structure of an Attenuated Quasi Species of HIV-1 from a Blood Transfusion Donor and Recipients , 1995, Science.

[31]  N. Sonenberg,et al.  A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. , 1990, Disease markers.

[32]  Jared E. Toettcher,et al.  Stochastic Gene Expression in a Lentiviral Positive-Feedback Loop: HIV-1 Tat Fluctuations Drive Phenotypic Diversity , 2005, Cell.

[33]  B. Berkhout,et al.  RNA interference against viruses: strike and counterstrike , 2007, Nature Biotechnology.

[34]  B. Ramratnam,et al.  Human Immunodeficiency Virus Type 1 Escape from RNA Interference , 2003, Journal of Virology.

[35]  B. Berkhout,et al.  Human Immunodeficiency Virus Type 1 Escape Is Restricted When Conserved Genome Sequences Are Targeted by RNA Interference , 2007, Journal of Virology.

[36]  Ding‐Shinn Chen,et al.  RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant , 2005, Gastroenterology.

[37]  M. Mathews,et al.  Adenovirus virus-associated RNA and translation control , 1991, Journal of virology.

[38]  J. Corbeil,et al.  A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  F. Clavel,et al.  HIV Drug Resistance , 2000, The New England journal of medicine.

[40]  D. Margolis,et al.  Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production , 1994, Journal of virology.

[41]  John J Rossi,et al.  Genetic therapies against HIV , 2007, Nature Biotechnology.

[42]  John J Rossi,et al.  Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  Andreas Meyerhans,et al.  Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations , 1989, Cell.

[44]  S. P. Walton,et al.  Impact of target mRNA structure on siRNA silencing efficiency: A large‐scale study , 2008, Biotechnology and bioengineering.

[45]  J. Rossi,et al.  Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  D. Schaffer,et al.  Selection of Novel Vesicular Stomatitis Virus Glycoprotein Variants from a Peptide Insertion Library for Enhanced Purification of Retroviral and Lentiviral Vectors , 2006, Journal of Virology.

[47]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[48]  J. Leonard,et al.  The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity , 1989, Journal of virology.

[49]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[50]  K. Metzner,et al.  Inhibition of drug-resistant HIV-1 by RNA interference. , 2006, Antiviral research.

[51]  M. Stevenson,et al.  Modulation of HIV-1 replication by RNA interference , 2002, Nature.

[52]  K. Feldmann,et al.  Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis. , 1998, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

[53]  E. Verdin,et al.  NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation , 2006, The EMBO journal.

[54]  Anne Gatignol,et al.  Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC , 2007, Nucleic acids research.

[55]  Kazunari Taira,et al.  Effects on RNAi of the tight structure, sequence and position of the targeted region. , 2004, Nucleic acids research.

[56]  J. Rossi,et al.  RNAi in Combination with a Ribozyme and TAR Decoy for Treatment of HIV Infection in Hematopoietic Cell Gene Therapy , 2006, Annals of the New York Academy of Sciences.

[57]  R. Desrosiers,et al.  Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. , 1994, AIDS research and human retroviruses.

[58]  Ben Berkhout,et al.  Silencing of HIV-1 with RNA interference: a multiple shRNA approach. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[59]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[60]  R. Desrosiers,et al.  Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. , 1994, AIDS research and human retroviruses.

[61]  J. Lieberman,et al.  Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. , 2005, Blood.

[62]  R. Harris,et al.  The DNA Deaminase Activity of Human APOBEC3G Is Required for Ty1, MusD, and Human Immunodeficiency Virus Type 1 Restriction , 2008, Journal of Virology.

[63]  Jin K. Wang,et al.  Evaluating the binding affinities of NF-κB p50 homodimer to the wild-type and single-nucleotide mutant Ig-κB sites by the unimolecular dsDNA microarray , 2003 .

[64]  Fred H. Gage,et al.  Development of a Self-Inactivating Lentivirus Vector , 1998, Journal of Virology.

[65]  J. Sodroski,et al.  A second post-transcriptional trans-activator gene required for HTLV-III replication , 1986, Nature.